CAMBRIDGE, Mass., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9 technology, has appointed Graeme Bell as its Chief Financial Officer. Mr. Bell succeeds Sapna Srivastava, Ph.D., who is transitioning to a senior advisory role within Intellia.
Mr. Bell joins Intellia from his role as Chief Financial Officer at Anacor Pharmaceuticals, Inc., a publicly traded biopharmaceutical company acquired by Pfizer, Inc. in June 2016. At Anacor, he led the finance, human resources, business development, IT, and facilities functions. Prior to Anacor, Mr. Bell spent more than 20 years at Merck & Co, Inc., where he held numerous finance and accounting senior-level positions including: CFO of U.S. operations, Controller, Global Pharmaceutical Franchises, CFO United Kingdom subsidiary, and head of investor relations. He is a Fellow of the Institute of Management Accountants with an MBA from the University of Durham, UK.
Mr. Bell will relocate to Intellia’s headquarters in Cambridge, Massachusetts, overseeing all financial functions including financial planning and analysis, financial reporting, treasury, tax, accounting, and finance. Additionally, Mr. Bell will be responsible for investor relations.
Dr. Srivastava has decided to transition from the Chief Financial and Strategy Officer role to a senior advisor primarily due to her personal commitments in New York City. Dr. Srivastava joined Intellia in April 2015, and played an integral role in helping start up Intellia’s financial operations and strategic direction, the Series B private funding, and the initial public offering. Dr. Srivastava is committed to ensuring a smooth transition of her responsibilities to Mr. Bell. At the conclusion of her advisory role, Dr. Srivastava will transition from Intellia.
“I want to thank Sapna for her significant contributions to ensuring that Intellia’s business strategy and public offering were successful,” said Chief Executive Officer and Founder Nessan Bermingham, Ph.D. “We welcome Graeme to his new role as he joins us for the next phase of growth in our company. We are excited about his extensive financial and operational experience and existing relationships with the investment community.”
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
